Cross-Reacting Material 197, a Specific Inhibitor of HB-EGF, and Its Anticancer Effects

Maryam Tanhapour; Abolfazl Golestani; Asad Vaisi-Raygani; Mahdi Aminian

doi:10.18502/bccr.v13i1.8828

Maryam Tanhapour Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abolfazl Golestani Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Asad Vaisi-Raygani Department of Clinical Biochemistry, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Mahdi Aminian Department of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

DOI: https://doi.org/10.18502/bccr.v13i1.8828

Keywords: Cancer, Cross-reacting materials 197 (CRM197), Diphtheria Toxin (DT), Epidermal growth factor receptor (EGFR), Heparin-binding EGF-like growth factor (HB-EGF)

Abstract

Genetic heterogeneity and metastasis remain the most challenging aspects of cancer treatment.Recent studies have introduced a mutant of diphtheria toxin,cross-reacting material197 (CRM197), as a new promising biological anticancer drug to improve cancer therapy in patients previously resistant to chemotherapy. Weak toxicity of CRM197accounts forthe stimulation ofcell apoptosis and the antitumor effect. Increasing evidence has indicated that the expression of heparin-binding epidermal growth factor-like (HB-EGF) growth factorincreases in most cancer cells, and CRM197 is its specific inhibitor.This study has focused on the structure, properties, and anticancer activity of CRM197.